The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.
Daraxonrasib plus gemcitabine and nab-paclitaxel received FDA breakthrough therapy designation for treatment-naive metastatic pancreatic adenocarcinoma.
The FDA has approved lutetium Lu 177 dotatate injection for SSTR-positive GEP-NETs, including foregut, midgut, and hindgut NETs.
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
Advertisement
Advertisement
Trending on OncLive
1
Zipalertinib + Chemotherapy Extends PFS by 6 Months in Frontline EGFR Exon 20 Insertion–Positive NSCLC
2
FDA Grants Breakthrough Therapy Designation to First-Line Daraxonrasib Plus Chemo in mPDAC
3
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
4
FDA Clears sNDA for Taletrectinib With Updated DOR Data in ROS1+ NSCLC
5